Prostate Cancer Metastases to Bone: Role of High Bone Turnover Induced by Androgen Deprivation
Abstract
Most patients with advanced prostate cancer have bone metastases. These metastases contribute significantly to the morbidity and mortality associated with advanced prostate cancer. Unfortunately, our knowledge of how and why prostate cancer metastasizes to bone is limited. The standard treatment for patients with advanced prostate cancer is androgen deprivation therapy. Treatment with androgen deprivation therapy leads to an increase in bone turnover as indicated by the loss of bone mineral density and the increase in markers of bone turnover in patients on treatment. This increase in bone turnover may result in an increase in bone metastases in patients with advanced prostate cancer. We have developed a mouse model which mimics the clinical scenario where men treated with androgen deprivation therapy develop bone metastases. Furthermore, we have used this model to test the effectiveness of zoledronic acid, a potent inhibitor of b%ne resorption, as a preventative treatment for prostate cancer bone metastases. Our data indicates that prevention of bone resorption by agents such as zoledronic acid beginning at onset of androgen deprivation therapy may result in significantly fewer bone metastases in patients with advanced prostate cancer.
Document Details
- Document Type
- Technical Report
- Publication Date
- May 01, 2002
- Accession Number
- ADA407345
Entities
People
- Susan S. Padalecki
Organizations
- University of Texas Health Science Center at San Antonio